Haleon Pakistan Limited (PSX:HALEON)

Pakistan · Delayed Price · Currency is PKR

786.29

-87.36 (-10.00%)

At close: Mar 2, 2026

-0.76% (1Y)

Market Cap	102.26B
Revenue (ttm)	41.88B
Net Income (ttm)	5.96B
Shares Out	117.05M
EPS (ttm)	50.93
PE Ratio	17.15
Forward PE	14.36
Dividend	30.00 (3.43%)
Ex-Dividend Date	Nov 4, 2025

Volume	91,195
Average Volume	27,085
Open	786.29
Previous Close	873.65
Day's Range	786.29 - 830.00
52-Week Range	653.14 - 1,010.00
Beta	0.40
RSI	36.73
Earnings Date	Feb 6, 2026

About Haleon Pakistan

Haleon Pakistan Limited engages in the manufacture, marketing, and sale of consumer healthcare products in Pakistan, rest of Asia, Africa, Australia, North America, the Middle East, and Europe. The company offers oral health, pain relief, wellness and nutrition, and respiratory health products, as well as over-the-counter pharmaceutical products. It sells its products primarily under the Panadol, CaC-1000 Plus, Sensodyne, paradontax, T-Day, ENO, Hydrozole, Qalsium-D, and Voltral Emulgel brands. The company also exports its products to Vietnam, ... [Read more]

Industry Pharmaceutical Preparations

Founded 2015

Employees 450

Stock Exchange Pakistan Stock Exchange

Ticker Symbol HALEON

Full Company Profile

Financial Performance

In 2024, Haleon Pakistan's revenue was 37.21 billion, an increase of 17.70% compared to the previous year's 31.61 billion. Earnings were 4.58 billion, an increase of 359.85%.

Financial Statements

News

There is no news available yet.